Nav: Home

GeoVax to collaborate with Georgia State on development of hepatitis B therapeutic vaccine

January 17, 2017

ATLANTA--The Georgia State University Research Foundation has entered into a research collaboration agreement with GeoVax Labs, Inc., a Georgia-based biotechnology company developing human vaccines, to advance development of a therapeutic vaccine for treatment of chronic Hepatitis B infections.

The Centers for Disease Control and Prevention estimates between 700,000 to 1.4 million people in the United States have chronic Hepatitis B virus infections, with an estimated 20,000 new infections every year.

The research collaboration will include the design, construction and characterization of multiple vaccine candidates by combining the preS VLP technology from Georgia State and GeoVax's MVA-VLP vaccine platform. Unique VLP design and functional assays developed by Dr. Ming Luo, professor in the Department of Chemistry at Georgia State, and performed in collaboration with Peking University Shenzhen Graduate School, will provide key information on vaccine effectiveness.

"My team's efforts continue to unveil the molecular mechanism of immune responses to HBV infection and we are excited to partner with GeoVax to further the development of a Hepatitis B therapeutic vaccine," said Dr. Luo. "Globally, chronic Hepatitis B affects more than 240 million people and contributes to nearly 686,000 deaths worldwide each year. By joining forces with GeoVax, we will apply our highly complementary sets of expertise in an effort to address the problem."

The vaccine will be based upon generating the preS VLP using the GeoVax's novel MVA-VLP vector platform, which has been proven safe in multiple human clinical trials of the company's preventive HIV vaccine. This platform is also being used to develop preventive vaccines against Zika virus and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg and Lassa.

"We are fortunate to have the collaboration with nearby Georgia State University and Dr. Ming Luo," said Farshad Guirakhoo, chief scientific officer at GeoVax. "The combined technologies and already defined functional assays will serve to rapidly test this innovative concept."
-end-


Georgia State University

Related Hepatitis Articles:

Hepatitis C increasing among pregnant women
Hepatitis C infections among pregnant women nearly doubled from 2009-2014, likely a consequence of the country's increasing opioid epidemic that is disproportionately affecting rural areas of states including Tennessee and West Virginia.
WHO's Global Hepatitis Report sets baseline to eliminate viral hepatitis by 2030
The World Hepatitis Alliance today welcomes the publication of the first-ever Global Hepatitis Report by the World Health Organization (WHO), which includes new data on the prevalence and global burden of viral hepatitis.
Elimination of viral hepatitis by 2030: What's needed and how do we get there?
This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly.
Discovery of new Hepatitis C virus mechanism
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions.
Is Europe ready to eliminate viral hepatitis?
Currently, Europe records around 57,000 newly diagnosed acute and chronic cases of hepatitis B and C each year.
Why baby boomers need a hepatitis C screening
Hepatitis C affects a disproportionate amount of older Americans, born between 1945 and 1965.
Counterattack of the hepatitis B virus
The hepatitis B virus (HBV) infects liver cells. Drugs are available to treat HBV, but they rarely cure the infection, and so the virus typically returns after the treatment ends.
Hepatitis C tied to increased risk of Parkinson's
The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the Dec.
The hepatitis A virus is of animal origin
The hepatitis A virus can trigger acute liver inflammation which generally has a mild course in small children but which can become dangerous in adults.
Modeling the helicase to understand hepatitis C
NS3 is an enzyme specific to the hepatitis C virus.

Related Hepatitis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...